These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24756193)

  • 1. Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.
    La Mantia L; Prone V; Marazzi MR; Erminio C; Protti A
    Neurol Sci; 2014 Sep; 35(9):1485-6. PubMed ID: 24756193
    [No Abstract]   [Full Text] [Related]  

  • 2. Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient.
    Piscolla E; Hakiki B; Pastò L; Razzolini L; Portaccio E; Amato MP
    J Neurol; 2013 Jun; 260(6):1675-7. PubMed ID: 23645219
    [No Abstract]   [Full Text] [Related]  

  • 3. Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.
    Tanaka M; Park K; Tanaka K
    Mult Scler; 2013 Aug; 19(9):1244-5. PubMed ID: 23322501
    [No Abstract]   [Full Text] [Related]  

  • 4. Rebound of disease activity during pregnancy after withdrawal of fingolimod.
    Sempere AP; Berenguer-Ruiz L; Feliu-Rey E
    Eur J Neurol; 2013 Aug; 20(8):e109-10. PubMed ID: 23829238
    [No Abstract]   [Full Text] [Related]  

  • 5. Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report.
    Leypoldt F; Münchau A; Moeller F; Bester M; Gerloff C; Heesen C
    Neurology; 2009 Mar; 72(11):1022-4. PubMed ID: 19289744
    [No Abstract]   [Full Text] [Related]  

  • 6. Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.
    Voon V; Saiva L; O'Kelly S; Keane D
    Eur J Clin Pharmacol; 2014 Mar; 70(3):373-5. PubMed ID: 24309839
    [No Abstract]   [Full Text] [Related]  

  • 7. [Infections and fingolimod].
    Cervera C
    Rev Neurol; 2012 Aug; 55(4):227-37. PubMed ID: 22829086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?
    Castrop F; Kowarik MC; Albrecht H; Krause M; Haslinger B; Zimmer C; Berthele A; Hemmer B
    Neurology; 2012 Mar; 78(12):928-30. PubMed ID: 22402856
    [No Abstract]   [Full Text] [Related]  

  • 9. Does fingolimod in multiple sclerosis patients cause macular edema?
    Turaka K; Bryan JS
    J Neurol; 2012 Feb; 259(2):386-8. PubMed ID: 22231867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.
    Pfender N; Jelcic I; Linnebank M; Schwarz U; Martin R
    Neurology; 2015 Jun; 84(23):2377-8. PubMed ID: 25957334
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sudden unexpected death on fingolimod.
    Lindsey JW; Haden-Pinneri K; Memon NB; Buja LM
    Mult Scler; 2012 Oct; 18(10):1507-8. PubMed ID: 22300970
    [No Abstract]   [Full Text] [Related]  

  • 13. Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.
    Al-Hashel J; Ahmed SF; Behbehani R; Alroughani R
    CNS Drugs; 2014 Sep; 28(9):817-24. PubMed ID: 25011422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis.
    van Rossum JA; Looysen EE; Daniels JM; Killestein J
    Mult Scler; 2014 Nov; 20(13):1792-3. PubMed ID: 24866203
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of fingolimod in relapsing-remitting multiple sclerosis.
    Sorensen PS
    Lancet Neurol; 2014 Jun; 13(6):526-7. PubMed ID: 24685277
    [No Abstract]   [Full Text] [Related]  

  • 16. Fingolimod in a patient with Wolff-Parkinson-White syndrome.
    Huys AC; Lalive PH; Sekoranja L
    Mult Scler; 2014 Apr; 20(5):636-7. PubMed ID: 23897641
    [No Abstract]   [Full Text] [Related]  

  • 17. Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.
    Thomas K; Schrötter H; Halank M; Ziemssen T
    BMC Neurol; 2014 Jun; 14():126. PubMed ID: 24906818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    Kappos L; Antel J; Comi G; Montalban X; O'Connor P; Polman CH; Haas T; Korn AA; Karlsson G; Radue EW;
    N Engl J Med; 2006 Sep; 355(11):1124-40. PubMed ID: 16971719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod for multiple sclerosis.
    Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
    Huggins A; Sergott RC
    Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.